PMV and Novalis in Rheavita Series A Round

Cresco acted as lead counsel to PMV and Novalis on their €2.5 million Series A investment in Rheavita.

RheaVita has developed the world’s first end-to-end continuous freeze-drying solution to address biopharmaceutical product development, manufacturing and supply needs in order to efficiently reach patients. RheaVita was founded in 2018 as a spin-out of Ghent University.

David Dessers led the Cresco team that advised the investors in this transaction.

More information on this transaction can be found in De Tijd.

For any further information or questions, please contact David Dessers.